Drug Profile

Bupivacaine buccal - Moberg Pharma

Alternative Names: BUPI; BUPI-25; Bupizenge

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oracain
Developer Hvidovre Hospital; Moberg Pharma
Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Dental pain; Inflammatory pain

Most Recent Events

16 Jan 2025 OncoZenge files for PCT patent application for bupivacaine buccal
07 Jan 2021 OncoZenge has patent protection for bupivacaine buccal in European Union
16 Nov 2020 Moberg Pharma plans a phase III registrational trial for Pain (Buccal) in Europe in early 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com